passifloricin A: polyketide alpha-pyrone from Passiflora foetida resin; structure in first source
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Passiflora | genus | A plant genus of the family Passifloraceae, order Violales, subclass Dilleniidae, class Magnoliopsida. They are vines with ornamental flowers and edible fruit.[MeSH] | Passifloraceae | A plant family of the order Violales, subclass Dilleniidae, class Magnoliopsida that are herbaceous or woody vines, shrubs, and trees, mostly of warm regions. Many have tendrils in leaf axils. Leaves are alternate. Flowers have 3-5 sepals, petals and stamens. Nearly all species have seeds that bear a fleshy appendage called an aril.[MeSH] |
Passiflora foetida | species | [no description available] | Passifloraceae | A plant family of the order Violales, subclass Dilleniidae, class Magnoliopsida that are herbaceous or woody vines, shrubs, and trees, mostly of warm regions. Many have tendrils in leaf axils. Leaves are alternate. Flowers have 3-5 sepals, petals and stamens. Nearly all species have seeds that bear a fleshy appendage called an aril.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 10928338 |
MeSH ID | M0395986 |
Synonym |
---|
passifloricin a |
(2r)-2-[(2s,4s,7s)-2,4,7-trihydroxyhenicosyl]-2,3-dihydropyran-6-one |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |